Wendy Chung

Biography
Wendy Chung is a leading figure in rare disease genomics and precision pediatrics. She has identified the genetic basis for more than 60 novel human Mendelian conditions and has helped define how genomic discovery can be translated into clinical care for children with rare and complex disorders. Her work has also been central to the implementation of genomic medicine at scale, including major efforts in autism and rare neurogenetic disease through SPARK and Simons Searchlight. More recently, she has helped lead the field toward genomic newborn screening through GUARDIAN, a large prospective study evaluating genome sequencing for early detection of rare, treatable conditions. Chung has also advanced a model for how genomic diagnosis can lead directly to personalized treatment, including work on antisense oligonucleotide therapy for KIF1A-associated neurological disorder. A member of the National Academy of Medicine, she continues to shape the future of rare disease diagnosis, newborn screening, and genomic implementation.

---

Talk
GUARDIAN genomic newborn screening
GUARDIAN is a pilot study that has demonstrated the feasibility and acceptability of genomic newborn screening within the public health setting. Screening over 25,000 newborns has diagnosed ~ 2.5% of newborns with treatable conditions.

Scott Grosse

Biography

F. Sessions Cole

Biography
F. Sessions Cole is an advocate for the patient- and research-informed model of care developed by the Undiagnosed Diseases Network which has solved ~1,000 medical mysteries through team science over the last 11 years. As a neonatologist, he contributed in the 1990s to the discovery of the first monogenic cause of progressive, lethal respiratory failure in term infants (surfactant protein B deficiency) and its treatment with infant lung transplantation. Since then, he has participated in the diagnosis of multiple ultra-rare genetic diseases among undiagnosed individuals. His research focuses on using advanced computational genomic analysis and a variety of cell- and model organism-based platforms for functional characterization of pathogenic variants in infants, children, and adults with undiagnosed and ultra-rare conditions. He has also led efforts to develop prioritization of mechanism-based, patient-informed therapeutic strategies for ultra-rare conditions.

Wendy Chung

Biography
Wendy Chung is a leading figure in rare disease genomics and precision pediatrics. She has identified the genetic basis for more than 60 novel human Mendelian conditions and has helped define how genomic discovery can be translated into clinical care for children with rare and complex disorders. Her work has also been central to the implementation of genomic medicine at scale, including major efforts in autism and rare neurogenetic disease through SPARK and Simons Searchlight. More recently, she has helped lead the field toward genomic newborn screening through GUARDIAN, a large prospective study evaluating genome sequencing for early detection of rare, treatable conditions. Chung has also advanced a model for how genomic diagnosis can lead directly to personalized treatment, including work on antisense oligonucleotide therapy for KIF1A-associated neurological disorder. A member of the National Academy of Medicine, she continues to shape the future of rare disease diagnosis, newborn screening, and genomic implementation.

MICHELE CAGGANA

Biography
Michele Caggana received her doctorate from the Harvard School of Public Health and completed a clinical molecular genetics fellowship at Mt. Sinai School of Medicine. She was boarded by the American Board of Medical Genetics, 1996-2025. Dr. Caggana retired from Wadsworth Center in 2025. She was the Deputy Director, Division of Genetics, Chief of the Laboratory of Human Genetics, and Director of the Newborn Screening (NBS) Program. She continues to work with the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL). She is a member/past Chair of APHL’s NBS Committee and the Molecular Subcommittee. Dr. Caggana served on the federal Advisory Committee for Heritable Disorders in Newborns and Children until its dissolution in 4/2025. She served on the National Advisory Child Health and Human Development Council. Dr. Caggana was funded by the NICHD, CDC, APHL and HRSA. Her career-long effort focused on molecular and genomic NBS.

Zhanzhi (Mike) Hu

Biography
Dr. Zhanzhi Hu (aka Mike) is a genetics researcher and a parent of two children with a rare disorder. He is an ardent advocate for newborn screening and focuses on using genomics to address the critical need of expanding the public health screening program. Mike cofounded Project GUARDIAN, a nonprofit organization with the mission of advancing genomics based newborn screening.

Heidi Cope

Biography
Ms. Cope directs Early Check, a statewide genomic newborn screening research program in North Carolina conducted in partnership with the North Carolina State Laboratory of Public Health and the University of North Carolina at Chapel Hill. She has extensive experience evaluating genes for inclusion in genomic newborn screening, including assessing gene¬-disease validity and clinical actionability. Her expertise also includes variant interpretation, return of results, and genomic counseling. Prior to joining Early Check, she spent 17 years in genomics research at Duke University Medical Center, using advanced genomic technologies to help end diagnostic odysseys and identify diagnoses for patients.

Mike Talkowski

Biography
Michael Talkowski received his Ph.D. in human genetics and trained in neurodevelopmental genomics as a postdoctoral fellow at Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard. His research program focuses on understanding the genetic etiology of disorders affecting prenatal, neonatal, and early childhood development, particularly autism and human developmental disorders. His group integrates molecular and computational approaches to explore the consequences of genomic variation with a particular interest in the relationship between genome structure and function and how this contributes to human disease, particularly neurodevelopmental disorders. Talkowski is currently the director of the Center for Genomic Medicine at Massachusetts General Hospital and a professor in the Department of Neurology at Harvard Medical School. He is also an institute member at the Broad Institute, where he co-leads the Broad Structural Variation Group and the NeuroDevelopmental Variability Initiative. He also co-directs several international consortia related to autism, fetal genomics and large-scale reference resources, including the genome aggregation database (gnomAD) and the All of Us Research Program.

Stan STC. Crooke

Biography
Dr. Stanley Crooke is founder, chairman and chief executive officer of n-Lorem, a nonprofit foundation focused on providing treatments for patients with nano-rare disease patients (1 to 30 patients worldwide), which he initiated in January 2020. Prior to n- Lorem, Dr. Crooke founded and was Chairman and Chief Executive Officer and Lead Scientist of Ionis Pharmaceuticals. During his tenure at Ionis, he led the scientific development of a new platform for drug discovery, antisense technology and the creation of one of the largest and more advanced development pipelines in the biotechnology industry, and commercialized several antisense drugs including, SPINRAZA® (nusinersen), TEGSEDI™ (inotersen) and others. Early in Dr. Crooke’s career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D (president) at SmithKline Beckman (now GSK). During his tenure at SKB, Dr. Crooke led the restructuring of R&D and the development of several drugs that were commercialized. Dr. Crooke has also contemporaneously led a successful academic career becoming a full professor at Baylor College of Medicine and the University of Pennsylvania Medical School where he trained a number of Ph.D. students and won several teaching awards. Dr. Crooke has been an active scientist throughout his career as well. Dr. Crooke has received a number of awards, most recently, the Indiana University School of Medicine Steven C. Beering Award, the Prix Galien Roy Vagelos Pro Bono Humanum Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award and the 2019 Massry Prize. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine, where he currently serves on the Board of Advisors. In 2021, Dr. Crooke has been named Distinguished Alumnus of both Baylor College of Medicine’s Graduate and Medical schools and named one of the 20 of the most influential biopharma R&D executives by Endpoints News. He has published nearly 600 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.

Elad Ziv

Biography
Dr. Elad Ziv is a primary care doctor and a specialist in internal medicine. Ziv's research focuses on the genetic epidemiology (how inherited factors play a role in disease) of breast cancer and other age-related diseases. He also studies groups of mixed ethnicity to understand the relationship between environmental and genetic risk factors in explaining differences in cancer incidence. Ziv earned his medical degree and completed a residency in internal medicine at UCSF. He completed a fellowship in internal medicine at the San Francisco Veterans Affairs Health Care System and later the UCSF general internal medicine research fellowship.

Eric Lander

Biography
Eric Lander is founding director and a core institute member of the Broad Institute of MIT and Harvard. A geneticist, molecular biologist, and mathematician, he has played a pioneering role in all aspects of the reading, understanding, and biomedical application of the human genome. He was a principal leader of the international Human Genome Project. As founding director, Lander plays a leading role in shaping the conception, development, distillation, and execution of Broad’s scientific directions to drive the Broad community’s shared impact. He also serves as a key mentor and strategist to Broad’s scientific community and administrative leadership, especially around issues of major strategic and scientific importance. A widely recognized scientific visionary, Lander has developed powerful methods for discovering the molecular basis of human diseases. Among them were the first methods for mapping the genes underlying diseases and traits in which dozens to hundreds of genes play a role — including heart disease, diabetes, schizophrenia, Alzheimer's disease, and even "monogenic" diseases like sickle cell disease. These paradigms have led to mapping of 100,000s of genetic variants associated with human diseases and traits, shedding light on the underlying biological mechanisms and leading to new and effective treatments. To enable this vision, Lander has been, for nearly forty years, a driving force in the discovery and characterization of the genetic information contained in the human genome. This work has included: the first human genome sequence; the human protein-coding gene; the genetic variants in the human populations; the non-coding regulatory controls; long, functional non-coding RNAs; three-dimensional folding of the human genome; and genome-wide screens to discover gene functions. Lander is professor of biology at MIT and professor of systems biology at Harvard Medical School. From 1991 to 2004, Lander founded and led the Whitehead/MIT Center for Genome Research, which became a flagship of the international Human Genome Project. In 2004, he founded the Broad Institute and served as its president and founding director through 2021. From 2009 to 2017, he served as co-chair of the President’s Council of Advisors on Science and Technology for President Barack Obama. From 2021 to 2022, he took a leave of absence to serve as President Biden’s Science Advisor and a member of his cabinet, as well as Director of the White House Office of Science and Technology Policy. In 2022, Lander launched Science for America, a solutions incubator focused on addressing urgent challenges including the climate and energy crisis, medicine and public health, and STEM equity and education. Lander’s honors and awards include the MacArthur Fellowship, the Breakthrough Prize in Life Sciences, the Albany Prize in Medicine and Biological Research, the Gairdner Foundation International Award of Canada, the Dan David Prize of Israel, the Mendel Medal of the Genetics Society in the UK, the City of Medicine Award, the Abelson Prize from the AAAS, the Award for Public Understanding of Science and Technology from the AAAS, the Woodrow Wilson Prize for Public Service from Princeton University, the James R. Killian Jr. Faculty Achievement Award from MIT, the William Allan Award from the American Society of Human Genetics, and 14 honorary doctorates.